Notably, Yu et al. (2017) demonstrated in vivo effects of Nrl knockout in three different RP models of differing genetic backgrounds, with Zhu et al. (2017) testing one further model, indicating its potential as a gene-agnostic treatment for RCDs. The gene discussed is NRL; the disease is retinitis pigmentosa 1.